INTRODUCTION
Lung cancer is the leading cause of cancer-related deaths in both women and men, and approximately 80% of the patients have non-small cell lung cancer (NSCLC). Because lung cancer is a deadly disease with a 5-year survival rate of less than 15%, a prognostic assessment of these patients is essential for treatment stratification. 1, 2 MicroRNA (miRNAs or miRs) are regulatory, non-coding RNAs about [21] [22] [23] nucleotides in length and are expressed at specific stages of tissue development, and have large-scale effects on the expression of a variety of genes at a post-transcriptional level. miRs are involved in many biological and pathological processes, and are emerging as highly tissue-specific biomarkers. 3, 4 Angiogenesis is defined as the growth of endothelial sprouts of pre-existing postcapillary venules and regarded as a hallmark in cancer development. 5, 6 Evidence is emerging that miRs are important players in endothelial cell biology and tumor angiogenesis. 5, 7 Dynamic changes in miR expression in response to growth factor stimulation or hypoxia imply that miRs are an integral component of the angiogenic program. 7 miR-126, a key positive regulator, promotes angiogenesis in response to angiogenic growth factors, such as vascular endothelial growth factor-A (VEGF-A). This is done by repressing negative regulators of signal transduction pathways. 7 In this context miR-126 work as an oncogene, but several studies have shown that miR-126 is down-regulated in different malignancies and is a potential tumor suppressor. [8] [9] [10] [11] miR-126 has also been shown to be down-regulated in lung cancer and in vitro and murine NSCLC studies have indicated that miR-126 restoration may down-regulate VEGF-A. [12] [13] [14] These contradictory results may indicate that miR-126 have several functions and is highly tissue specific. NSCLC classification according to histology and nodal status are two of the most important determinants for NSCLC treatment strategies. 15, 16 However, a 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 considerable variability in prognosis has been observed for subsets of patients with the same histological or clinical features. Consequently, the clinical incorporation of predictive and prognostic molecular biomarkers together with traditional cancer staging should improve the management of patients with NSCLC.
Considering the previous conflicting results regarding impact of miR-126, our hypothesis is that miR-126 may have different prognostic impacts within NSCLC subgroups.
In an unselected NSCLC cohort of 335 patients, 17 we aimed to explore possible prognostic roles by miR-126 in all NSCLC cases and subgroups according to histology and nodal status, using in situ hybridization and a high throughput TMA platform. Further, we examined the correlations between VEGF-A and miR-126 and the prognostic impacts of their coexpression. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
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PATIENTS AND METHODS
Patients and Clinical Samples
Primary tumor tissues from anonymized patients diagnosed with NSCLC pathologic stage I to IIIA at the University Hospital of North Norway (UNN) and Nordland Central Hospital (NLCH) from 1990 through 2004 were used in this retrospective study. In total, 371 patients were registered from the hospital database. Of these, 36 patients were excluded from the study due to: (i) Radiotherapy or chemotherapy prior to surgery (n = 10); (ii) Other malignancy within five years prior to NSCLC diagnosis (n = 13); (iii) Inadequate paraffin-embedded fixed tissue blocks (n = 13). Adjuvant chemotherapy was not introduced in Norway during this period (1990 -2004 Ethics approved the study.
Microarray construction
All lung cancer cases were histologically reviewed by two pathologists (S.A.S. and K.A.S.) and the most representative areas of viable tumor cells were carefully selected. The TMAs were assembled using a tissue-arraying instrument (Beecher Instruments, Silver Springs, MD). The Detailed methodology has been previously reported. 17 Briefly, we used a 0.6 mm 
In Situ Hybridization (ISH)
The method used for in situ hybridization is based on a protocol developed by Nuovo et al, 19 with minor adjustments. 
Immunohistochemistry (IHC)
The detailed VEGF-A (rabbit polyclonal; RB-1678; Neomarkers, CA; 1:10) IHC procedure has been previously published. 17, 20 All TMA stainings were done in one single experiment.
Scoring of ISH and IHC
The ARIOL imaging system (Genetix, San Jose, CA) was used to scan the TMA slides of ISH staining. The slides were loaded in the automated loader (Applied Imaging SL 50) and specimens were scanned at low (1.25×) and high resolution (20×) using the Olympus BX 61 microscope with an automated platform (Prior). Representative and viable tissue sections were scored manually and semiquantitatively for cytoplasmic staining on a computer screen.
The dominant staining intensity in tumor cells was scored as: 0 = negative; 1 = weak; 2 = intermediate; 3 = strong ( Figure 1 ). In case of disagreement (score discrepancy > 1), the slides were re-examined and a consensus was reached by the observers. In most cores there was a mixture of stromal cells and tumor cells. By morphological criteria only tumor cells were scored for staining intensity.
All samples were anonymized and independently scored by one experienced pathologist and one technician (S.W.S. and K.L.). When assessing a variable for a given core, the observers were blinded to the scores of the other observer and to outcome. Mean score for each case was calculated from all four cores and both examiners. High expression of miR-126 in tumor cells was defined as a mean score ≥ 2. For VEGF-A, the same cut-off value as previously published was used.
17,21
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Statistical Methods
All statistical analyses were done using the statistical package SPSS (Chicago, IL), version 17. The Chi-square test and Fishers Exact test were used to examine the association between molecular marker expression and various clinicopathological parameters. The ISH scores from each observer were compared for interobserver reliability by use of a two-way random effect model with absolute agreement definition. The intraclass correlation coefficient (reliability coefficient) was obtained from these results. Plots of the disease-specific survival (DSS) according to marker expression were drawn using the Kaplan-Meier method, and statistical significance between survival curves was assessed by the log rank test. DSS was determined from the date of surgery to the time of lung cancer death. The multivariate analysis was carried out using the Cox proportional hazards model. Only variables of significant value from the univariate analysis were entered into the Cox regression analysis.
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RESULTS
Clinocopathologic Variables
Demographic, clinical, and histopathologic variables are shown in 
Interobserver Variability
Interobserver scoring agreement was tested for miR-126. The scoring agreement was good (r = 0.91, P < 0.001). There were no significant correlations between miR-126 expression levels and any of the clinicopathological variables except for histology (P = 0.039). There was a higher frequency of high miR-126 expression in SCCs (22.7%) compared to ACs (11.7%) and LCCs (10.7%) (P = 0.039). There was a weak, but significant, correlation between miR-126 and VEGF-A (r = 0.12, κ = 0.10, P = 0.037). In low respective high miR-126 expression group, the percentage of high VEGF-A expression was 41% and 57%. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Univariate Analysis Survival analyses according to clinicopathological variables are shown Table 1 . Performance status (P = 0.013), histological differentiation (P < 0.001), surgical procedure (P < 0.004), pathological stage (P < 0.001), T-stage (P < 0.001), N-stage (P < 0.001) and vascular infiltration (P < 0.001) were all significant prognostic indicators for DSS. In the total material, miR-126 expression was a significant negative prognostic marker (Figure 2A , P = 0.005).
Expression of miR-126 and Correlations
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Stratified by histology, high miR-126 expression was a significant negative prognostic marker in SCCs ( Figure 2B , P < 0.001), but not in ACs ( Figure 2C , P = 0.61) or LCCs (P = 0.65). Stratified by nodal status, high miR-126 expression was significant associated with a poor prognosis in lymph node positive patients ( Figure 2E , P<0.001), but not in lymph node negative patients ( Figure 2D , P = 0.39).
Multivariate Cox Proportional Hazard Analysis
In the total material (Table 2) , performance status (P = 0.027), pathological T-stage (P = 0.001), N-stage (P < 0.001), histological differentiation (P = 0.038), vascular infiltration (P = 0.01) and miR-126 (P = 0.028) were all independent prognostic factors.
Stratified by histology, miR-126 was an independent negative prognostic factor (HR 2.6, CI95% 1.5-4.5, P < 0.001) in SCCs. Stratified by lymph node status, miR-126 was independently associated with a dismal prognosis (HR 3.4, CI95%1.8-6.3, P<0.001) in lymph node positive patients.
Co-expression VEGF-A and miR-126
We have previously presented the prognostic impact of VEGF-A in the same tumor material. 17 Herein, we have used the same cut-off value, but because of a survival update in 2008 the follow-up time is prolonged. According to the tumor cell VEGF-A expression, the 5- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 year survival rates were 48% (high expression, n =142) versus 66% (low expression, n =192) (P= 0.001) after the survival update.
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The co-expression of miR-126 and VEGF-A had a significant (P=0.002) prognostic impact in the univariate analysis ( Figure 3 ) as low/low (n=150), mixed (n=129) and high/high (n=35) expression resulted in 5-year survival rates of 68%, 51% and 42%, respectively. In the multivariate analysis, these co-expressions of VEGF-A and miR-126 also had an independent prognostic impact (P=0.018). For patients with high VEGF-A/high miR-126 expression, HR was 2.2, (CI95% 1.3-3.8, P=0.005) compared to patients who had low VEGF-A/low miR-126 expression. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
Page 12 of 22 Cancer
DISCUSSION
We present the first large-scale study combining high-throughput TMA and in situ hybridization to evaluate the prognostic impact of miR-126 expression. In this unselected population of surgically resected NSCLC patients, high miR-126 expression is an independent negative prognostic factor in the total cohort. However, the prognostic impact is strongly related to those with SCCs or regional nodal metastasis. Moreover, there was a weak, although significant association between VEGF-A and miR-126 expression, and the coexpression of VEGF-A and miR-126 was a strong independent negative prognostic factor. miRNAs are well preserved in formalin-fixed tissue, making them attractive candidates for use in routinely processed tissue materials. 22, 23 Most of the previous studies on miRNA expression were done on microarrays using RNA extracted from human cancer tissue 24 Using RNA extracts from whole tumors, this finding would easily be missed. As miR-126 often is down-regulated in tumor cells compared to stromal tissue, using RNA extracts may have led to erroneous results for this marker.
To our knowledge, this is the first study to explore the prognostic impact of miR-126 in a larger cancer cohort. miR-126 has been found down-regulated in several malignancies such as cervical 8 , breast 9 , colorectal 10 , and gastric cancer 11 and was perceived a tumor suppressor, although, the prognostic impact was not addressed in these studies. Also in NSCLC, miR-126 has been interpreted as a tumor suppressor. [12] [13] [14] In a combined in vitro and in vivo murine NSCLC study, Liu et al concluded that miR-126 inhibits VEGF-A expression.
It should be noted that adenocarcinoma lung cancer cell lines were used in this study.
Interestingly, we observe a significantly higher frequency of high miR-126 expression in SCCs when compared to ACs and LCCs, and the marker is a strong negative independent prognostic factor for the SCCs subgroup only. It is noteworthy that treatment responses and side effects from novel therapies have lately been correlated to NSCLC histology subgroups, and ACs and SSCs are increasingly recognized as different diseases instead of one. Regarding anti-angiogenic treatment in NSCLC, the VEGF monoclonal antibody, bevacizumab, is only given to non-SCCs due to the risk of fatal bleeding in SCCs. 25 Supporting our findings, miR-126 is also found to be an important positive stimulator of angiogenesis. 5, 26 However, its angiogenic function has so far been mostly studied in the 
5,26
We observed a weak but significant correlation between high VEGF-A and high miR-126 expression in the tumor cells, indicating that a similar connection may be present in the cancer cells. However, as there were several patients with high VEGF-A expression without high mir-126 expression, it indicates that miR-126 is only one of many potential VEGF-A regulators. Nevertheless, the co-expression of VEGF-A and miR-126 is independently associated with a poor prognosis.
In the clinic, valid prognostic markers in the subpopulation of N+ patients are warranted. Among lymph node positive patients, high miR-126 expression was a strong independent negative prognostic factor. Indeed, 19 out of 21 N+ patients with high miR-126 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 expression had a lung cancer related death within 5-years after diagnosis. Further studies are needed to address the question why miR-126 has such a strong prognostic impact in this subgroup.
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